The timely treatment of STEMI varies substantially at the hospital level, for both primary presentation and transfers, and worse outcomes were observed in patients when the first medical contact (FMC) ...

Two studies published in JACC on June 16 provide new insights on arterial events associated with heritable thoracic aortic disease (TAD) and the relative risk in patients with pathogenic variants (PVs ...

Registration is now open for ACC Legislative Conference 2025, taking place Oct. 5-7 in Washington, DC. Join the ACC Advocacy team to learn more about health policy, network with fellow ACC Advocates ...

As part of ACC's ongoing involvement in the American Medical Association (AMA)/Specialty Society Relative Value Scale Update Committee (RUC) process, the College distributes RUC physician work surveys ...

Primary TR is caused by structural abnormalities of the valve itself, which can be related to valve degeneration or trauma, congenital anomaly, infection or an infiltrative process (tumors, drugs or ...

Implementation among patients with persistently uncontrolled BP showed the most significant health and economic benefits. For instance, in patients with persistent, uncontrolled hypertension, (defined ...

"Chair"-Side Thoughts on Atlanta. Cardiology asked Drachman, Berlacher and Guibone for their thoughts on Atlanta and where you might find them, when not at the Georgia World Congress Center. "Atlanta ...

Pulmonary embolism (PE) continues to challenge clinicians with its complex presentation and potential for rapid deterioration. As the third leading cause of cardiovascular mortality in the U.S.

Treatment. Anticoagulation should be initiated as soon as the diagnosis of PE is suspected. 8 Unfractionated heparin may be preferred in patients who are candidates for further advanced therapies such ...

The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol was a welcome update from the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular ...

Table 1: Phase 2 and 3 Trials of Novel Therapies Targeting LPA Gene Transcription Rate Using siRNAs and Gene Translation With ASOs.Courtesy of Alebna PL, Mehta A. a OCEAN(a) DOSE (Olpasiran Trials of ...

Contact: Olivia Walther, owalther@acc.org, WASHINGTON (Dec 11, 2023) - A world without cardiovascular disease (CVD) is possible, yet millions of lives are lost prematurely to heart disease each year, ...